{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:26:57Z","timestamp":1790342817992,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1136\/ijgc-2024-005567","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T14:19:41Z","timestamp":1722262781000},"page":"1580-1587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["2009 International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer: oncologic outcomes based on involvement of adnexa, serosa, or both"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-8775","authenticated-orcid":false,"given":"Eric","family":"Rios-Doria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9689-1298","authenticated-orcid":false,"given":"Nadeem R","family":"Abu-Rustum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9413-316X","authenticated-orcid":false,"given":"Gretchen","family":"Glaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"McGree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane Gerda","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyhan","family":"Ataseven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaled","family":"Alektiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitriy","family":"Zamarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0818-3836","authenticated-orcid":false,"suffix":"Jr","given":"Mario L","family":"Leitao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0365-7510","authenticated-orcid":false,"given":"Jennifer","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2024-005567_bb0010","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2024-005567_bb0015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1136\/ijgc-2024-005567_bb0020","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/AOG.0b013e3181f39849","article-title":"Comparative performance of the 2009 International Federation of Gynecology and Obstetrics\u2019 staging system for uterine corpus cancer","volume":"116","author":"Lewin","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2024-005567_bb0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijgo.2009.02.010","article-title":"Revised FIGO staging for carcinoma of the endometrium","volume":"105","author":"Creasman","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1136\/ijgc-2024-005567_bb0030","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/COC.0b013e31829c12be","article-title":"Survival analysis of cancer patients with FIGO stage IIIA endometrial cancer","volume":"38","author":"Lum","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005567_bb0035","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ygyno.2009.04.030","article-title":"Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer","volume":"114","author":"Havrilesky","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005567_bb0040","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ygyno.2014.08.022","article-title":"The outcome and efficacy of adjuvant chemotherapy alone in patients with stage IIIA endometrial carcinoma with solitary adnexal involvement: a retrospective single-institution study","volume":"135","author":"Lan","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005567_bb0045","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/ijgc-2019-000643","article-title":"SATEN III-splitting adjuvant treatment of stage III endometrial cancers: an international, multicenter study","volume":"29","author":"Kahramanoglu","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005567_bb0050","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1006\/gyno.1999.5415","article-title":"The significance of adnexal involvement in endometrial carcinoma","volume":"74","author":"Connell","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005567_bb0055","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/962518","article-title":"Outcome of endometrial cancer stage IIIA with adnexa or serosal involvement only","volume":"2011","author":"Jobsen","year":"2011","journal-title":"Obstet Gynecol Int"},{"key":"10.1136\/ijgc-2024-005567_bb0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/gyno.2002.6744","article-title":"The impact of positive peritoneal washings and serosal and adnexal involvement on survival in patients with stage IIIA uterine cancer","volume":"86","author":"Preyer","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005567_bb0065","article-title":"Current practice patterns in nodal evaluation and adjuvant treatment of advanced stage endometrioid endometrial cancer: an SGO survey","volume":"34","author":"Parker","year":"2020","journal-title":"Gynecol Oncol Rep"},{"key":"10.1136\/ijgc-2024-005567_bb0070","unstructured":"National Comprehensive Cancer Network . Uterine neoplasms (version 2.2023). Available: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uterine.pdf [Accessed 14 Jul 2023]."},{"key":"10.1136\/ijgc-2024-005567_bb0075","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ijgc-2021-002884","article-title":"Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial cancer","volume":"31","author":"Montes de Oca","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005567_bb0080","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ijrobp.2007.02.003","article-title":"Analysis of prognostic factors and patterns of recurrence in patients with pathologic stage III endometrial cancer","volume":"68","author":"Patel","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2024-005567_bb0085","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.ijrobp.2016.12.035","article-title":"Brachytherapy improves survival in stage III endometrial cancer with cervical involvement","volume":"97","author":"Bingham","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2024-005567_bb0090","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2018.11.002","article-title":"Adjuvant therapy in stage III endometrial cancer confined to the pelvis","volume":"152","author":"Albeesh","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005567_bb0095","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ygyno.2016.03.021","article-title":"Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: patterns of care and impact on overall survival","volume":"141","author":"Boothe","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005567_bb0100","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2013.06.024","article-title":"Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin\/paclitaxel for stage III (FIGO 2009) endometrial cancer","volume":"130","author":"Milgrom","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005567_bb0105","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2024-005567_bb0110","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2024-005567_bb0115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ygyno.2005.03.033","article-title":"Practice patterns of SGO members for stage IIIA endometrial cancer","volume":"98","author":"Lee","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005567_bb0120","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1471-0528.1989.tb03341.x","article-title":"Revised FIGO staging for gynaecological cancer","volume":"96","author":"Shepherd","year":"1989","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1136\/ijgc-2024-005567_bb0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.2004.00.7617","article-title":"Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"24","author":"Randall","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005567_bb0130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ygyno.2006.02.007","article-title":"Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin\/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer","volume":"103","author":"Greven","year":"2006","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24035801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24035801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2024-005567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T20:30:56Z","timestamp":1759350656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24035801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1048891X24035801"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2024-005567","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2009 International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer: oncologic outcomes based on involvement of adnexa, serosa, or both","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2024-005567","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}